MELTZER LESLIE (CIK 2084030) reported 9 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-05-14). Recent activity: Sell APLS (107,024 shares), Buy APLS (22,610 shares), Sell APLS (22,610 shares), Buy APLS (45,220 shares), Sell APLS (45,220 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Research and Development | Sell | 107,024 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Research and Development | Buy | 22,610 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Research and Development | Sell | 22,610 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Research and Development | Buy | 45,220 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Research and Development | Sell | 45,220 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Research and Development | Sell | 61,804 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Research and Development | Sell | 45,220 | $0 |
| 2026-01-30 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Research and Development | Buy | 45,220 | $0 |
| 2025-09-02 | Apellis Pharmaceuticals, Inc. (APLS) | Chief Research and Development | Buy | 61,804 | $0 |
Source: SEC Form 4 filings · as of 2026-05-14